Assessment of Dose Proportionality, Absolute Bioavailability, and Immunogenicity Response of CTLA4Ig (BMS-188667), a Novel Immunosuppressive Agent, Following Subcutaneous and Intravenous Administration to Rats

被引：0
作者：
Nuggehally R. Srinivas
Wen Chyi Shyu
Russell S. Weiner
Garvin Warner
Charles Comereski
Lee K. Tay
Douglas S. Greene
Rashmi H. Barbhaiya
机构：
[1] Bristol-Myers Squibb Pharmaceutical Research Institute,Department of Metabolism and Pharmacokinetics
[2] Bristol-Myers Squibb Pharmaceutical Research Institute,Department of Metabolism and Pharmacokinetics
[3] Bristol-Myers Squibb Pharmaceutical Research Institute,Department of Drug Safety Evaluation
来源：
Pharmaceutical Research | 1997年 / 14卷
关键词：
CTLA4Ig; intravenous; subcutaneous; pharmacokinetics; immunogenicity; rats;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose. The objectives of this study were: to delineate the pharmacokinetics of CTLA4Ig in rats after single and multiple intravenous (IV) and subcutaneous (SC) doses; to assess the relationship of the pharmacokinetic parameters of CTLA4Ig vs dose; to calculate the SC absolute bioavailability; and to assess the antibody response of CTLA4Ig.
引用
收藏
页码：911 / 916
页数：5
相关论文
共 154 条
[81]  
Thistlewaith J. R.(undefined)undefined undefined undefined undefined-undefined
[82]  
Montage A.(undefined)undefined undefined undefined undefined-undefined
[83]  
Brady W.(undefined)undefined undefined undefined undefined-undefined
[84]  
Gibson M. G.(undefined)undefined undefined undefined undefined-undefined
[85]  
Linsley P. S.(undefined)undefined undefined undefined undefined-undefined
[86]  
Bluestone J. A.(undefined)undefined undefined undefined undefined-undefined
[87]  
Riegelman S.(undefined)undefined undefined undefined undefined-undefined
[88]  
Collier P.(undefined)undefined undefined undefined undefined-undefined
[89]  
Stute N.(undefined)undefined undefined undefined undefined-undefined
[90]  
Furman W. L.(undefined)undefined undefined undefined undefined-undefined
45678910111213